Evidence map›Paper›PMID 30846862›Full record

ArticleLeukemia2019

Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia.

Jonathan Canaani, Myriam Labopin, Maija Itälä-Remes, Didier Blaise, Gerard Socié, Edouard Forcade, Johan Maertens, Depei Wu, Ram Malladi, Jan J Cornelissen and 5 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Review
  15. HighHemaSphere · 2020
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 7 countries.

Jonathan CanaaniHematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel.
Myriam LabopinEBMT Paris study office / CEREST-TC, Saint Antoine Hospital, Paris, France.
Maija Itälä-RemesStem Cell Transplantation Unit, HUCH Comprehensive Cancer Center, Helsinki, Finland.
Didier BlaiseProgramme de Transplantation & Thérapie Cellulaire, Institut Paoli Calmettes, Marseille, France.ORCID http://orcid.org/0000-0002-5684-9447
Gerard SociéHematology Department, Hopital St. Louis, Paris, France.ORCID http://orcid.org/0000-0002-2114-7533
Edouard ForcadeCHU Bordeaux Hôpital Haut-Leveque, Pessac, France.
Johan MaertensHematology Department, University Hospital Gasthuisberg, Leuven, Belgium.
Depei WuHematology Department, First Affiliated Hospital of Soochow University, Suzhou, China.
Ram MalladiHematology Department, Queen Elizabeth Medical Centre, Birmingham, UK.
Jan J CornelissenHematology Department, University Medical Center Rotterdam, Rotterdam, Netherlands.
Anne HuynhInstitut Universitaire du Cancer de Toulouse, Toulouse, France.
Jean Henri BourhisHematology Division, Gustave Roussy institut de cancérologie, Villejuif, France.
Jordi EsteveHematology Department, Hospital Clínic de Barcelona, Barcelona, Spain.
Mohamad MohtyEBMT Paris study office / CEREST-TC, Saint Antoine Hospital, Paris, France.
Arnon NaglerHematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel. Arnon.nagler@sheba.health.gov.il.
Hôpital Saint-Antoine · FRTel Aviv University · ILHôpital Cardiologique du Haut-Lévêque · FRHôpital Saint-Louis · FRHospital Clínic de Barcelona · ESInstitut Gustave Roussy · FRInstitut Paoli-Calmettes · FRQueen Elizabeth Hospital Birmingham · GBRotterdam University of Applied Sciences · NLSoochow University · CNUniversitair Ziekenhuis Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Baseline cytogenetic studies at diagnosis remain the single most important determinant of outcome in patients with acute myeloid leukemia (AML). However, the prognostic role of the complete gamut of cytogenetic aberrations in AML patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently undefined. In addition, their significance in conjunction with FLT3-ITD status has not been addressed thus far. Using the ALWP/EBMT registry we conducted a retrospective analysis to determine the clinical outcomes of AML patients undergoing allo-HSCT with respect to specific recurring cytogenetic abnormalities complemented with FLT3-ITD status. We analyzed a cohort consisting of 8558 adult AML patients who underwent allo-HSCT from either a matched sibling or a matched unrelated donor. Patients with inv(3)(q21q26)/t(3;3)(q21;q26), del(5q), monosomy 7, chromosome 17p abnormalities, t(10;11)(p11-14;q13-23), t(6;11)(q27;q23), as well as those patients with a monosomal or complex karyotype experienced significantly inferior leukemia-free survival (LFS) compared to patients with a normal karyotype. Trisomy 14, del(9q), and loss of chromosome X were associated with improved LFS rates. A novel prognostic model delineating 5 distinct groups incorporating cytogenetic complexity and FLT3-ITD status was constructed with significant prognostic implications. Our analysis supports the added prognostic significance of FLT3-ITD to baseline cytogenetics in patients undergoing allo-HSCT.

Indexed as

Chromosome AberrationsAdolescentAdultAgedfms-Like Tyrosine Kinase 3Hematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMiddle AgedMutationPrognosisYoung AdultFLT3 protein, humanfms-Like Tyrosine Kinase 3

Identifiers

PMID30846862
OpenAlexW2918237637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.